Clinical Efficacy of Dapagliflozin in the Treatment of Patients with Diabetic Nephropathy and Its Effect on Proteinuria Level
Ze-Jun Jin,Gen-Zhen Wang
DOI: https://doi.org/10.2147/DMSO.S421579
2023-07-23
Abstract:Ze-Jun Jin, Gen-Zhen Wang Department of Nephrology, Anhui Wannan Rehabilitation Hospital, Wuhu, Anhui, People's Republic of China Correspondence: Gen-Zhen Wang, Email Objective: This study aimed to analyze the clinical efficacy of dapagliflozin in the treatment of diabetic kidney disease and its impact on proteinuria levels in patients. Methods: Retrospective analysis of medical records of 176 patients with diabetic kidney disease treated at our hospital from January 2020 to January 2022. According to the different treatment methods, the patients were divided into a control group (n=88) receiving enalapril maleate treatment and an observation group (n=88) receiving dapagliflozin treatment. The clinical treatment effects, blood glucose levels, renal function indicators, inflammation factor indicators, and adverse reactions were compared between the two groups. Results: The total effective rate of treatment (97.73%) in the observation group was significantly higher than that (79.55%) in the control group (P< 0.05). After treatment, the FPG, 2hPG, and HbAlc levels in the observation group were significantly lower than those in the control group (P< 0.05). After treatment, the Scr, BUN, UmAlb, UAER, UACR, and 24-hour urine protein quantitative levels in the observation group were significantly lower than those in the control group (P< 0.05). After treatment, the hs-CRP, IL-1β, and TNF-α levels in the observation group were significantly lower than those in the control group (P< 0.05). The incidence of adverse reactions in the observation group significantly lower than the control group (P< 0.05). Conclusion: Compared with enalapril maleate alone, the combined application of dapagliflozin in the treatment of diabetic kidney disease has more significant clinical efficacy. It can further control patients' blood sugar, reduce their body's inflammatory response, alleviate or eliminate their proteinuria symptoms, promote the recovery of their renal function, and enhance the safety of their treatment to a certain extent, which helps to further improve the clinical treatment effect of patients. Keywords: stroke, nursing, hemiplegic limb rehabilitation training nursing, effect analysis Diabetic nephropathy refers to kidney damage caused by diabetes, which is one of the most common complications of diabetes. The main manifestations of diabetic nephropathy are proteinuria, hypertension, and kidney function damage, which seriously affect the quality of life and long-term survival rate of patients. 1 Currently, common treatments for diabetic nephropathy in clinical practice include blood glucose control, blood pressure control, and kidney protection therapy. 2 Currently, agents are promising and have good availability to be used as inhibitors of DKD progression to new advanced stages of CKD and ACEI, ARB. As for monoclonal antibodies that play a role in inhibiting TGF-betha expression, they are still not available and expensive. Therefore, DM drugs given orally may have better availability. The progression of DKD to advanced stage of CKD is through increased expression of TGF-betha. 3 TGF-betha expression was found to be higher in patients with persistent proteinuria. 4 In recent years, an increasing number of studies 5,6 have shown that dapagliflozin can not only control blood glucose levels in diabetic patients, but can also reduce their risk of cardiovascular events and death, and has significant renal protective effects. However, clinical studies on the treatment of diabetic nephropathy with dapagliflozin are still limited. Therefore, this study aims to analyze the clinical efficacy of dapagliflozin in treating diabetic nephropathy and its impact on patients' proteinuria levels, providing reference for the clinical treatment of diabetic nephropathy. This study will compare the clinical efficacy and safety of treating diabetic nephropathy patients with either monotherapy of enalapril maleate or dapagliflozin, thereby providing new ideas for the treatment of diabetic nephropathy. Retrospective analysis of medical records of 176 patients with diabetic kidney disease treated at our hospital from January 2020 to January 2022. Basic information such as gender, age, duration of diabetes, duration of diabetic nephropathy, and disease staging were collected. All patients met the inclusion criteria and were divided into two groups according to different treatment methods: the control group (n=88) received treatment with enalapril maleate, while the observation group (n=88) received treatment with dapagliflozin. This study has been approved by the ethics committee of Anhui Wannan Rehabilitation Hospital. Patients and their families were informed of the research content and volunta -Abstract Truncated-
endocrinology & metabolism